4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Patient-derived tumor spheroid cultures as a promising tool to assist personalized therapeutic decisions in breast cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Breast cancer is the most common cause of cancer related deaths in women. Treatment of breast cancer has many limitations including a lack of accurate biomarkers to predict success of chemotherapy and intrinsic resistance of a significant group of patients to the gold standard of therapy. Therefore, new tools are needed to provide doctors with guidance in choosing the most effective treatment plan for a particular patient and thus to increase the survival rate for breast cancer patients.

          Methods

          Here, we present a successful method to grow in vitro spheroids from primary breast cancer tissue. Samples were received in accordance with relevant ethical guidelines and regulations. After tissue dissociation, in vitro spheroids were generated in a scaffold-free 96-well plate format. Spheroid composition was investigated by immunohistochemistry (IHC) of epithelial [pan cytokeratin (panCK)], stromal (vimentin) and breast cancer-specific markers (ER, PR, HER2, GATA). Growth and cell viability of the spheroids were assessed upon treatment with multiple anti-cancer compounds. Student’s t-test and two-way ANOVA test were used to determine statistical significance.

          Results

          We were able to successfully grow spheroids from 27 out of 31 samples from surgical resections of breast cancer tissue from previously untreated patients. Recapitulation of the histopathology of the tissue of origin was confirmed. Furthermore, a drug panel of standard first-line chemotherapy drugs used to treat breast cancer was applied to assess the viability of the patient-derived spheroids and revealed variation between samples in the response of the spheroids to different drug treatments.

          Conclusions

          We investigated the feasibility and the utility of an in vitro, patient-derived spheroid model for breast cancer therapy, and we conclude that spheroids serve as a highly effective platform to explore cancer therapeutics and personalized treatment efficacy. These results have significant implications for the application of this model in clinical personalized medicine.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: found
          • Article: not found

          Breast Cancer Treatment

          Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

              The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.
                Bookmark

                Author and article information

                Journal
                Transl Cancer Res
                Transl Cancer Res
                TCR
                Translational Cancer Research
                AME Publishing Company
                2218-676X
                2219-6803
                January 2022
                January 2022
                : 11
                : 1
                : 134-147
                Affiliations
                [1 ]Institute for Personalized and Translational Medicine, Ariel University, Ariel , Israel;
                [2 ]Brigham and Women’s Hospital , Boston, MA, USA
                Author notes

                Contributions: (I) Conception and design: R Cohen-Harazi, S Hofmann; (II) Administrative support: Y Maizels, I Koman; (III) Provision of study materials or patients: S Hofmann, R Cohen-Harazi, Y Maizels; (IV) Collection and assembly of data: R Cohen-Harazi, S Hofmann, Y Maizels; (V) Data analysis and interpretation: R Cohen-Harazi, S Hofmann, Y Maizels; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

                [#]

                These authors contributed equally to this work.

                Correspondence to: Raichel Cohen-Harazi. Institute for Personalized and Translational Medicine, Ariel University, Ariel 40700, Israel. Email: raichelha@ 123456ariel.ac.il .
                [^]

                ORCID: 0000-0002-2360-9463.

                Article
                tcr-11-01-134
                10.21037/tcr-21-1577
                8841497
                35261891
                8c6a3e3e-b797-4a73-a415-8c45dec23b77
                2022 Translational Cancer Research. All rights reserved.

                Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

                History
                : 09 August 2021
                : 16 November 2021
                Categories
                Original Article

                three dimensional (3d) models,personalized medicine,patient-derived spheroids,breast cancer

                Comments

                Comment on this article